2.16 | 8.37%
| Price and Volume | |
|---|---|
| Recent Price | 27.96 |
| 52 Week High | 28.11 |
| 52 Week Low | 8.03 |
| Avg. Daily Vol. (Mil) | 4.32 |
| Beta (3 year) | 1.35 |
| Share Related Items | |
| Mkt Cap (Mil) | 4,553.35 |
| Shares Out (Mil) | 162.85 |
| Float (Mil) | 118.50 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.20 |
| Current Ratio | 1.90 |
| LT Debt/ Equity | 200.14 |
| Total Debt / Equity | 209.01 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 6.99 |
| Price/Book | 549.19 |
| Price/Cash Flow | -8.40 |
| Per Share Data | |
| Earnings | -4.14 |
| Sales | 4.00 |
| Book Value | 0.05 |
| Cash Flow | -3.34 |
| Business Summary | |
|---|---|
| Amylin Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of innovative medicines for the treatment of diabetes, obesity and other diseases. | |
| General Information | |
| 9360 Towne Centre Drive
San Diego, CA 92121 |
|
| www.amylin.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 1300 | |
| CEO: Daniel M. Bradbury | |
| Short Interest | |
| Current Month (Mil) | 10.40 |
| Previous Month (Mil) | 10.50 |
| Short Interest Ratio (Days) | 3.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -30.10 |
| Return on Investments | -36.00 |
| Profitability | |
| Gross Margin | 97.50 |
| EBIT Margin | -79.30 |
| Profit Margin | -92.90 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet